HPV DETECTION AND 13 HIGH RISK SUBTYPES

HPV Detection and 13 High Risk Subtypes is an advanced molecular diagnostic test used to detect Human Papillomavirus (HPV) infection and identify 13 high-risk HPV genotypes associated with cervical cancer and other HPV-related malignancies. The test utilizes highly sensitive molecular technology to detect viral DNA and assess cancer risk associated with persistent HPV infection.

Human Papillomavirus is one of the most common sexually transmitted viral infections worldwide. While many HPV infections resolve naturally, persistent infection with high-risk HPV types can lead to cervical cancer, anal cancer, vaginal cancer, vulvar cancer, penile cancer, and certain head and neck cancers. Early detection of high-risk HPV infection is essential for preventive care and timely medical intervention.

Benefits of the Test

• Detects Human Papillomavirus infection accurately.
• Identifies 13 clinically significant high-risk HPV subtypes.
• Supports early cervical cancer risk assessment.
• Helps detect infection before symptoms develop.
• Useful alongside Pap smear screening.
• Provides reliable molecular diagnostic results.
• Supports preventive healthcare and monitoring.
• Assists doctors in clinical decision-making.

Why Doctors Recommend This Test

Doctors recommend HPV Detection and 13 High Risk Subtypes testing for women undergoing cervical cancer screening, individuals with abnormal Pap smear results, patients with persistent HPV infection, and those requiring comprehensive HPV risk assessment.

The test helps identify high-risk HPV infections that may increase the likelihood of developing cervical precancerous changes and cancer.

Preparation Before Test

• No fasting is required.
• A cervical sample is typically collected by a healthcare professional.
• Avoid vaginal medications, douches, or intercourse for 24–48 hours before sample collection if advised.
• Inform your doctor about pregnancy or recent gynecological procedures.
• Follow all specimen collection instructions carefully.
• Provide relevant medical history when available.

Normal Reporting Time

Most HPV Detection and 13 High Risk Subtypes reports at Focus Diagnostics are available within 2–3 hours for specimen processing and molecular workflow initiation. Final HPV DNA analysis, subtype identification, validation, and reporting are generally completed within a few working days depending on laboratory protocols and quality assurance procedures.

Who Should Take This Test?

This test may be recommended for:

• Women undergoing routine cervical cancer screening.
• Patients with abnormal Pap smear results.
• Individuals with persistent HPV infection.
• Women above the recommended screening age.
• Patients with cervical dysplasia.
• Individuals at increased risk of HPV-related cancers.
• Patients referred by gynecologists.
• People requiring comprehensive HPV evaluation.

Detailed Information

Human Papillomavirus (HPV) is a group of more than 200 related viruses, some of which are classified as high-risk because they are associated with cancer development. Persistent infection with high-risk HPV types is recognized as the primary cause of cervical cancer and contributes to several other cancers affecting both men and women.

The most significant high-risk HPV types include HPV 16, HPV 18, and several additional oncogenic subtypes. Although most HPV infections resolve spontaneously through the body's immune response, some infections persist and can cause abnormal cellular changes over time.

HPV Detection and 13 High Risk Subtypes testing uses advanced molecular methods to identify the presence of HPV DNA and determine whether one or more high-risk genotypes are present. The test is more sensitive than traditional cytology alone and provides valuable information for risk assessment.

The test is commonly used alongside cervical cytology (Pap smear) as part of cervical cancer screening programs. Women with positive high-risk HPV results may require closer monitoring, repeat testing, colposcopy, or additional diagnostic evaluation depending on clinical findings.

Detection of high-risk HPV does not mean cancer is present. Instead, it indicates an increased risk that requires appropriate follow-up and medical evaluation. Early identification allows healthcare providers to intervene before significant disease develops.

Results should always be interpreted alongside Pap smear findings, clinical examination, colposcopy results, and physician evaluation. Follow-up recommendations depend on age, HPV subtype, and associated clinical findings.

At Focus Diagnostics, HPV Detection and 13 High Risk Subtypes testing is performed using advanced molecular diagnostic platforms, validated HPV DNA detection technologies, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful screening results.